The Role of Collagenase Clostridium histolyticum in Dupuytren’s Disease: A Systematic Review
DOI:
https://doi.org/10.25759/spmfr.477Keywords:
Clostridium histolyticum, Dupuytren Contracture, Microbial CollagenaseAbstract
Introduction: Dupuytren’s disease (DD) is a benign and progressive fibroproliferative disease that involves the palmar fascia, where collagenous cords form from the overlay of nodular fibrotic tissue. Clostridium histolyticum collagenase (CHC) is a minimally invasive option for the treatment of advanced DD. CHC allows collagen lysis, leading to the rupture of fibrous cords. This review aims to reflect on the existing scientific evidence about the role of CHC in the treatment of DD.Methods: The study presented is a systematic review. Authors followed PRISMA reporting guidelines. The search was performed using the following databases: PubMed, ClinicalTrials.gov and Cochrane Central Registry of Controlled Trials (CENTRAL). As inclusion criteria, randomized and non-randomized clinical trials and observational studies were considered. As an exclusion criterion, all studies not written in English were excluded. The primary outcome was efficacy, through reduced contracture or increased range of motion. Safety/adverse effects, degree of contracture recurrence and patient satisfaction with the application of this technique were considered secondary outcomes. All relevant articles were systematically reviewed by 2 reviewers.
Results: The search resulted in 30 studies, 15 of which were selected by 2 independent reviewers. CHC therapy was shown to be superior in efficacy when compared to placebo and similar results when compared to surgical options. Regarding secondary outcomes, CHC therapy proved to be a safe treatment with a high patient satisfaction, with low recurrence rates and similar recurrence rates after surgical treatments with 5 years of follow-up.
Conclusion: CHC has proven to be an effective and safe therapy in DD patients, as well as a non-invasive alternative to surgery.
References
Pess GM, Sundbom M, Wilson K, Lindqvist D, Dahlin LB. A post hoc analysis of Dupuytren contracture treated with collagenase Clostridium histolyticum across disease stages. J Plast Surg Hand Surg. 2018;52:301-6. doi: 10.1080/2000656X.2018.1484753.
McGrouther DA, Jenkins A, Brown S, Gerber RA, Szczypa P, Cohen B. The efficacy and safety of collagenase clostridium histolyticum in the treatment of patients with moderate Dupuytren's contracture. Curr Med Res Opin. 2014;30:733-9. doi: 10.1185/03007995.2013.874990.
Gilpin D, Coleman S, Hall S, Houston A, Karrasch J, Jones N. Injectable collagenase Clostridium histolyticum: a new nonsurgical treatment for Dupuytren's disease. J Hand Surg Am. 2010;35:2027-38.e1. doi: 10.1016/ j.jhsa2010.08.007.
Witthaut J, Bushmakin AG, Gerber RA, Cappelleri JC, Le Graverand-Gastineau MP. Determining clinically important changes in range of motion in patients with Dupuytren's Contracture: secondary analysis of the randomized, double-blind, placebo-controlled CORD I study. Clin Drug Investig. 2011;31:791-8. doi: 10.1007/BF03256918.
Badalamente MA, Hurst LC, Benhaim P, Cohen BM. Efficacy and safety of collagenase clostridium histolyticum in the treatment of proximal interphalangeal joints in dupuytren contracture: combined analysis of 4 phase 3 clinical trials. J Hand Surg Am. 2015;40:975-83. doi: 10.1016/j.jhsa. 2015.02.018.
Gaston RG, Larsen SE, Pess GM, Coleman S, Dean B, Cohen BM, et al. The Efficacy and Safety of Concurrent Collagenase Clostridium Histolyticum Injections for 2 Dupuytren Contractures in the Same Hand: A Prospective, Multicenter Study. J Hand Surg Am. 2015;40:1963-71. doi: 10.1016/j.jhsa. 2015.06.099.
Peimer CA, Blazar P, Coleman S, Kaplan FT, Smith T, Lindau T. Dupuytren Contracture Recurrence Following Treatment with Collagenase Clostridium histolyticum (CORDLESS [Collagenase Option for Reduction of Dupuytren Long-Term Evaluation of Safety Study]): 5-Year Data. J Hand Surg Am. 2015;40:1597-605. doi: 10.1016/j.jhsa.2015.04.036.
Bear BJ, Peimer CA, Kaplan FTD, Kaufman GJ, Tursi JP, Smith T. Treatment of Recurrent Dupuytren Contracture in Joints Previously Effectively Treated With Collagenase Clostridium histolyticum. J Hand Surg Am. 2017;42:391.e1-391.e8. doi: 10.1016/j.jhsa.2017.02.010.
Hurst LC, Badalamente MA, Hentz VR, Hotchkiss RN, Kaplan FT, Meals RA, et al. Injectable collagenase clostridium histolyticum for Dupuytren's contracture. N Engl J Med. 2009;361:968-79. doi: 10.1056/NEJMoa0810866.
Costas B, Coleman S, Kaufman G, James R, Cohen B, Gaston RG. Efficacy and safety of collagenase clostridium histolyticum for Dupuytren disease nodules: a randomized controlled trial. BMC Musculoskelet Disord. 2017;18:374. doi: 10.1186/s12891-017-1713-z.
Lawrence Hurst. Collagenase in the treatment of Dupuytren disease. Registry name identifier: NCT00260429
BainbridgeC,GerberRA,SzczypaPP,SmithT,KushnerH,CohenB,etal. Efficacy of collagenase in patients who did and did not have previous hand surgery for Dupuytren's contracture. J Plast Surg Hand Surg. 2012;46:177-83. doi: 10.3109/2000656X.2012.683795.
Abe Y. Comparison of Treatment Outcomes after Collagenase Injection and Percutaneous Needle Fasciotomy for Dupuytren's Contracture: Objective and Subjective Comparisons with a 3-Year Follow-Up. Plast Reconstr Surg. 2020;145:1464-74. doi: 10.1097/PRS.0000000000006828.
Byström M, Ibsen Sörensen A, Samuelsson K, Fridén JO, Strömberg J. Five-Year Results of a Randomized, Controlled Trial of Collagenase Treatment Compared With Needle Fasciotomy for Dupuytren Contracture. J Hand Surg Am. 2022;47:211-7. doi: 10.1016/j.jhsa.2021.11.019.
Gruber JS, Zhang D, Janssen SJ, Blazar P, Jupiter JB, Earp BE. Limited Fasciectomy Versus Collagenase Clostridium histolyticum for Dupuytren Contracture: A Propensity Score Matched Study of Single Digit Treatment with Minimum 5 Years of Telephone Follow-Up. J Hand Surg Am. 2021;46:888-95. doi: 10.1016/j.jhsa.2021.05.022.
Downloads
Published
How to Cite
Issue
Section
License
Copyright statement
Authors must also submit a copyright statement (as seen below) on article submission.
To the Editor-in-chief of the SPMFR Journal:
The below signed author(s) hereby state that the article
________________________________________ (ref. MFR_________) is
an original unpublished work and all facts stated are a product of the author(s) investigation. This article does not violate any copyright laws or privacy statements. The author(s) also hereby confirm that there is no conflict of interest's issues in this article.
By submitting this article the author(s) agree that after publication all copyrights belong to the SPMFR Journal.
Signed by all authors
Date:
Names (capital letters):
Signatures:
The SPMFR Journal’s contents are follow a Creative Commons licence. After publication the authors can hand out the articles as long as the SPMFR Journal is credited.
